Can't find what you are looking for?
Try our search navigation!

MusclePharm to Present Importance of Nutritional Therapy for AIDS Patients at the American Public Health Association

 DENVER CO — November 2, 2010: MusclePharm® Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, today announced they have been invited to present at the 138th Annual Meeting of the American Public Health Association in Denver, CO on Wednesday, November 10, 2010. The Company will discuss the benefits of its nutritional supplement program for HIV/AIDS patients.

The Annual Meeting of the American Public Health Association is one of the oldest and largest public health meetings in the nation. Representatives of Federal and State health agencies will attend, including the FDA, CDC, NIH, CMS, and the Department of Health and Human Services among others.

MusclePharm’s presentation panel discussion will discuss, Innovative Approaches to Therapeutic HIV Design, and will illustrate how nutritional supplementation has a positive effect on patients with AIDS Wasting Syndrome.

Dr. Roscoe M. Moore Jr., MusclePharm’s Chief Scientific Director and former Assistant U.S. Surgeon General commented, “MusclePharm is pleased to participate in the American Public Health Association’s Annual Meeting. Therapeutic nutritional supplementation products, like those provided by MusclePharm, are essential in maintaining the health status of HIV/AIDS patients receiving antiretroviral therapies.”

Dr. Moore continued, “MusclePharm continues to work to provide the most effective evidenced-based approach to produce products that will further mitigate the impact and progression of wasting syndrome in HIV/AIDS patients.”

The U.S. Health Resources and Services Administration (HRSA) found that weight loss and muscle wasting remain a significant nutritional concern for people with HIV/AIDS. HRSA said, "HIV associated wasting results in loss primarily of lean body mass. Such depletion increases the likelihood of opportunistic infections and is an independent predictor of increased morbidity and mortality, even if total body weight is maintained.”